Program Overview
The MDSF ASH 2024 Symposium will focus on challenges the MDS community faces in 2024. Progress has been made in understanding the biology, genetics and pathogenesis of MDS. Prognostication, and treatment strategies have been improved, but not satisfactorily. In 2024 we are still facing problems: Can we assess minimal residual disease? We are still debating regarding the recommended Hb threshold for RBC transfusions. The increasing role of inflammation in the disease pathogenesis, raises the question of anti-inflammatory treatment. The reports on germline mutations and their role in MDS in adulthood might change our genetic screening policy. Finally, we are still puzzled whether patients with higher-risk disease should be treated with hypomethylating agents only, as the only proven treatment, or additional therapy might improve the outcome. The symposium will highlight these challenges, and based on recent advances in the field, potential solutions will be presented and discussed.
Target Audience
This activity is designed for an audience of nurses, pharmacists, physicians, and physician associates.
Learning Objectives
Participants will learn about novel information obtained over the last decade and will hear about potential applications in the field of MDS.
More specifically practitioners and researchers:
- Attendees will learn about MRD in MDS
- They will face the question of liberal vs restrictive RBC transfusion policy, and what’s next or in addition to RBC transfusions in LR-MDS
- They will become familiar with the role of inflammation in the pathogenesis of the disease and the potential application of MDS anti-inflammatory treatment.
- The symposium participants will hear about germline mutations and the dilemma of whom of the family members or others should be screened for mutations.
- They will attend the debate whether to continue treating patients with HR-MDS with hypomethylating agents only or should we prefer combination treatments.
- Patient discussion will complete the educational lessons by combining scientific evidence with practical real-life issues. These discussion will focus on patients with LR- and HR-MDS
Claim Your Credits for Attending the Symposium!
Thank you for joining us at the event on Friday, December 6, 2024. If you attended, you may be eligible to claim credits.
Speakers
Lionel Adès, MD, PhD
Rena Buckstein, MD, FRCPC
Aristoteles Giagounidis, MD
Jaroslaw Maciejewski, MD, PhD, FACP
Moshe Mittelman, MD
Ghulam J. Mufti, MD, FRCP, FRCPath
Stephen D. Nimer, MD
Esther Oliva, MD
Casey L. O’Connell, MD
Magnus Tobiasson, MD, PhD
Lachelle Weeks, MD, PhD
Outputs
Access to the meeting outputs are available below by clicking on each topic.
Our Supporters
Thank you to Agios Pharmaceuticals, Inc, Bristol-Myers Squibb, Geron Corporation, Keros Therapeutics, Notable, Rigel Pharmaceuticals, Inc, and Taiho Oncology for supporting this initiative.
